Drug Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Alzheimer's Disease
Eptastigmine Improves Cognitive Performance and Global Functioning
March 31st, 2000
In a recent study, researchers from Italy found eptastigmine improves cognitive performance and global functioning in mild-to-moderate Alzheimer's disease (AD) patients. "The study was designed as a randomized, double-blind, placebo-controlled, parallel-group study," reported B.P. Imbimbo and colleagues. The study consisted of 349 outpatients in 26 Italian and American geriatric and neurological centers. All of the patients had been diagnosed as having probable AD as determined by the National Institute of Neurological and Communicative Disorders and Stroke and the AD and Related Disorders Association. Researchers divided the...
Source: Drug Week (2000-03-31)
|
